Trial Profile
A Randomized, Controlled, Double-blind Study to Evaluate Efficacy and Survival of Combining Nimotuzumab Plus Concurrent Chemo-radiotherapy in Loco-regional Esophageal Squamous Cell Carcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2023
Price :
$35
*
At a glance
- Drugs Nimotuzumab (Primary) ; Cisplatin; Paclitaxel
- Indications Oesophageal cancer; Squamous cell cancer
- Focus Therapeutic Use
- 20 Oct 2023 Status changed from recruiting to active, no longer recruiting, according to Results published in the British Journal of Cancer.
- 20 Oct 2023 Interim results assessing efficacy and safety of nimotuzumab plus concurrent chemo-radiotherapy in patients with unresectable locally advanced oesophageal squamous cell carcinoma, published in the British Journal of Cancer
- 07 Jun 2022 Interim results presented at the 58th Annual Meeting of the American Society of Clinical Oncology